, Agence Nationale de Sécurité du Médicament

;. -laboratoire-cerba and . Caillon, Bactericidal effect of daptomycin compared with vancomycin and teicoplanin against gram-positive bacteria, Caractéristiques de la teicoplanine, vol.37, pp.540-548, 1989.

, Antibiogramme de la Société Française de Micorbiologie (CASFM) -Recommandations, 2018.

-. C. Matthews, Increased teicoplanin doses are associated with improved serum levels but not drug toxicity, J. Infect, vol.68, issue.1, pp.43-49, 2014.

-. D. Bugano, Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection, Einstein (Sao Paulo), vol.9, issue.3, pp.265-282, 2011.

-. Nakamura, Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections, J. Infect. Chemother, vol.21, issue.6, pp.449-455, 2015.

-. Pea, Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, Journal of Antimicrobial Chemotherapy, vol.51, issue.4, pp.971-975, 2003.

-. Wang, Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections, Basic Clin. Pharmacol. Toxicol, vol.110, issue.5, pp.416-420, 2012.

-. Dong, An assessment of teicoplanin use and monitoring serum levels in a Chinese teaching hospital, Int J Clin Pharmacol Ther, vol.49, issue.1, pp.14-22, 2011.

-. A. Smithers, Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers, Antimicrob. Agents Chemother, vol.36, issue.1, pp.115-120, 1992.

-. Bourguignon, Pharmacokinetics of teicoplanin in the elderly : construction of a model for therapeutic drug monitoring, J Pharm Clin, vol.27, pp.189-194, 2008.

K. Matsumoto, Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections, J. Infect. Chemother, vol.16, issue.3, pp.193-199, 2010.

-. Ueda, High-dose regimen to achieve novel target trough concentration in teicoplanin, J. Infect. Chemother, vol.20, issue.1, pp.43-47, 2014.

-. Nakano, Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis, Int J Clin Pharm, vol.38, issue.4, pp.908-914, 2016.

, Société Française d'Anesthésie et de Réanimation, Recommandations formalisées d'experts -Administration des antibiotiques en réanimation -2017

-. S. Harbarth, Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis, Am J Med, vol.115, pp.529-535, 2003.

-. Shiraishi, Elimination of teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, teicoplanin and vancomycin followed by in vitro haemodiafiltration models for teicoplanin, Anaesth Intensive Care, vol.40, issue.3, pp.442-449, 2012.

-. S. Lim, High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration, Hemodial Int, vol.23, issue.1, pp.69-76, 2019.

-. , Mise au point sur le bon usage des aminosides administrés par voie injectable : gentamicine, tobramycine, nétilmycine, amikacine -propriétés pharmacologiques, indications, posologies et modes d'administration, surveillance du traitement, 2011.